Melody G. Duvall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Melody G. Duvall has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
- Bruce David Levy
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
14 shared publications Elliot Israel
6 shared publicationsNandini Krishnamoorthy
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
6 shared publicationsEugene R. Bleecker
Department of Medicine, Mayo Clinic, Scottsdale, USA
4 shared publicationsSerpil C. Erzurum
Lerner Research Institute, Cleveland Clinic, Cleveland, USA
4 shared publicationsBrenda R. Phillips
Division of Statistics and Bioinformatics, Department of Public Health Sciences, Pennsylvania State University, Hershey, USA
3 shared publications
Latest Publications
- 3 November 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
As-needed inhaled corticosteroids in asthma: an Official American Thoracic Society clinical practice guideline
Background: Inhaled corticosteroid (ICS)-containing reliever therapy has demonstrated efficacy in improving asthma outcomes when compared to short-acting beta2-agonists (SABA) alone but remains underutilized. The purpose of this guideline is to provide recommendations surrounding the use of combination ICS-formoterol or ICS+SABA (in combination or separate inhalers) as reliever therapy across the asthma severity spectrum in adolescents and adults. Methods: The American Thoracic Society clinical practice guideline panel evaluated six research questions in the PICO format addressing the use of ICS-containing reliever therapy across National Asthma Education and Prevention Program (NAEPP) asthma treatment steps 1-5. The methodology team conducted systematic literature reviews and GRADE assessments, which the panel utilized to inform the recommendations for each specific PICO and overall. Recommendations: In patients at NAEPP steps 1 and 2, the panel made strong recommendations for the use of as-needed-only ICS-SABA or ICS-formoterol over SABA-only therapy, and conditional recommendations over scheduled ICS + as-needed SABA. In patients at NAEPP steps 3-5, the taskforce made a strong recommendation for the use of maintenance-and-reliever therapy (MART) with ICS-formoterol over scheduled ICS-LABA plus as-needed SABA. In patients at NAEPP steps 3-5 who are using scheduled maintenance ICS-LABA, the panel made a conditional recommendation for use of ICS+SABA reliever over SABA reliever. In considering these recommendations, the panel valued the importance of preventing severe exacerbations and considered the risk of SABA-only treatment, as well as ICS and systemic corticosteroid (SCS) exposure. Conclusions: This clinical practice guideline, informed by systematic reviews and GRADE-based appraisals of PICO-framed evidence, makes these evidence-based recommendations for the safe and effective use of ICS-containing reliever therapy in asthma.
- 3 November 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
As-needed inhaled corticosteroids in asthma: an Official American Thoracic Society clinical practice guideline
Background: Inhaled corticosteroid (ICS)-containing reliever therapy has demonstrated efficacy in improving asthma outcomes when compared to short-acting beta2-agonists (SABA) alone but remains underutilized. The purpose of this guideline is to provide recommendations surrounding the use of combination ICS-formoterol or ICS+SABA (in combination or separate inhalers) as reliever therapy across the asthma severity spectrum in adolescents and adults. Methods: The American Thoracic Society clinical practice guideline panel evaluated six research questions in the PICO format addressing the use of ICS-containing reliever therapy across National Asthma Education and Prevention Program (NAEPP) asthma treatment steps 1-5. The methodology team conducted systematic literature reviews and GRADE assessments, which the panel utilized to inform the recommendations for each specific PICO and overall. Recommendations: In patients at NAEPP steps 1 and 2, the panel made strong recommendations for the use of as-needed-only ICS-SABA or ICS-formoterol over SABA-only therapy, and conditional recommendations over scheduled ICS + as-needed SABA. In patients at NAEPP steps 3-5, the taskforce made a strong recommendation for the use of maintenance-and-reliever therapy (MART) with ICS-formoterol over scheduled ICS-LABA plus as-needed SABA. In patients at NAEPP steps 3-5 who are using scheduled maintenance ICS-LABA, the panel made a conditional recommendation for use of ICS+SABA reliever over SABA reliever. In considering these recommendations, the panel valued the importance of preventing severe exacerbations and considered the risk of SABA-only treatment, as well as ICS and systemic corticosteroid (SCS) exposure. Conclusions: This clinical practice guideline, informed by systematic reviews and GRADE-based appraisals of PICO-framed evidence, makes these evidence-based recommendations for the safe and effective use of ICS-containing reliever therapy in asthma.
- Open Access
- 11 October 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- p. 2600317
Dysregulated NK cell phenotype in exacerbation-prone severe asthma
Background: Natural killer (NK) cell dysfunction and defective inflammation resolution pathways are associated with chronic airway inflammation in asthma. NK cells are targets for regulation by essential polyunsaturated fatty acid-derived specialized pro-resolving mediators (SPMs), including resolvin D2 (RvD2), to stimulate inflammation resolution. Methods: Multiparameter flow cytometry was utilized to examine expression patterns of select activating and inhibitory receptors, including the RvD2 receptor DRV2, on circulating NK cells in SARP3 severe and non-severe asthma subjects and healthy controls. Plasma RvD2 and serum amyloid A (SAA) was measured, and RvD2 and SAA regulation of NK cell cytotoxicity was examined in vitro . Results: Expansion of circulating NK cells with downregulated activating receptors NKp30 and NKp46 and inhibitory receptor CD161 were linked with exacerbation susceptibility and longitudinal lung function trajectory in asthma. Circulating SAA levels were higher in severe asthma patients (median 8.8 μg·mL −1 ) than healthy individuals (2.2 μg·mL −1 ; p=0.003). In contrast, plasma RvD2 levels were lower in severe asthma (153 pg·mL −1 versus 208 pg·mL −1 in health; p=0.041), concomitant with a two-fold higher NK cell DRV2 receptor expression than in non-severe asthma subjects (3973 MFI versus 1798; p=0.003). High-dose SAA exposure downregulated NK cell triggering receptors and resulted in a 22% suppression of cytotoxicity (48.9±9.7% versus 62.5±9.2% in vehicle; p=0.001). In contrast, RvD2 enhanced NK cell cytotoxicity (38.1±8.8% versus 33.1±8.3%; p=0.007) and partially reversed SAA-mediated suppression (5.4±2.7% change; p=0.031). Conclusions: These findings identify a perturbed counterregulatory network for inflammation resolution in severe asthma comprised of excess pro-inflammatory SAA, deficient pro-resolving RvD2, and altered NK cell immune signatures that were associated with increased asthma morbidity. The beneficial impact of RvD2 in counteracting SAA-mediated suppression of NK cell effector function supports a pivotal mechanistic role for SPMs to enhance cell-type specific resolution pathways to combat persistent airway inflammation in asthma.
- 11 October 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- p. 2600317
Open AccessDysregulated NK cell phenotype in exacerbation-prone severe asthma
Background: Natural killer (NK) cell dysfunction and defective inflammation resolution pathways are associated with chronic airway inflammation in asthma. NK cells are targets for regulation by essential polyunsaturated fatty acid-derived specialized pro-resolving mediators (SPMs), including resolvin D2 (RvD2), to stimulate inflammation resolution. Methods: Multiparameter flow cytometry was utilized to examine expression patterns of select activating and inhibitory receptors, including the RvD2 receptor DRV2, on circulating NK cells in SARP3 severe and non-severe asthma subjects and healthy controls. Plasma RvD2 and serum amyloid A (SAA) was measured, and RvD2 and SAA regulation of NK cell cytotoxicity was examined in vitro . Results: Expansion of circulating NK cells with downregulated activating receptors NKp30 and NKp46 and inhibitory receptor CD161 were linked with exacerbation susceptibility and longitudinal lung function trajectory in asthma. Circulating SAA levels were higher in severe asthma patients (median 8.8 μg·mL −1 ) than healthy individuals (2.2 μg·mL −1 ; p=0.003). In contrast, plasma RvD2 levels were lower in severe asthma (153 pg·mL −1 versus 208 pg·mL −1 in health; p=0.041), concomitant with a two-fold higher NK cell DRV2 receptor expression than in non-severe asthma subjects (3973 MFI versus 1798; p=0.003). High-dose SAA exposure downregulated NK cell triggering receptors and resulted in a 22% suppression of cytotoxicity (48.9±9.7% versus 62.5±9.2% in vehicle; p=0.001). In contrast, RvD2 enhanced NK cell cytotoxicity (38.1±8.8% versus 33.1±8.3%; p=0.007) and partially reversed SAA-mediated suppression (5.4±2.7% change; p=0.031). Conclusions: These findings identify a perturbed counterregulatory network for inflammation resolution in severe asthma comprised of excess pro-inflammatory SAA, deficient pro-resolving RvD2, and altered NK cell immune signatures that were associated with increased asthma morbidity. The beneficial impact of RvD2 in counteracting SAA-mediated suppression of NK cell effector function supports a pivotal mechanistic role for SPMs to enhance cell-type specific resolution pathways to combat persistent airway inflammation in asthma.
- Open Access
- 10 July 2026
- Published by Springer Nature in Respiratory Research
Lower plasma resolvin D1 level and greater sputum eosinophilia characterize a cluster of severe asthma patients
Severe asthma is a chronic disease of airway inflammation with substantial morbidity. Deficient specialized pro-resolving mediators (SPMs) are associated w
- 10 July 2026
- Published by Springer Nature in Respiratory Research
Open AccessLower plasma resolvin D1 level and greater sputum eosinophilia characterize a cluster of severe asthma patients
Severe asthma is a chronic disease of airway inflammation with substantial morbidity. Deficient specialized pro-resolving mediators (SPMs) are associated w
- 19 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (114) , eaeb2657
Siglec-F + neutrophils promote the resolution of acute lung injury through ALOX15 induction
Neutrophils have vital proinflammatory protective functions, but gene expression changes in neutrophils found in inflamed tissues suggest additional proresolving effects. We identified a neutrophil subset with a distinct phenotype and function that emerges in mouse lungs during resolution of injury. These resolution-phase neutrophils increased expression of Siglec-F (sialic acid–binding Ig-like lectin F), Alox15 (12/15-lipoxygenase), and Csf1 ( colony-stimulating factor 1 ). Siglec-F + neutrophils promoted macrophage differentiation and produced specialized proresolving mediators that accelerated injury resolution. Neutrophil depletion hindered lung epithelial catabatic responses, whereas adoptive transfer of Siglec-F + neutrophils accelerated restitution of lung epithelial cells. Transforming growth factor–β (TGF-β) and granulocyte-macrophage colony-stimulating factor (GM-CSF), acting via activator protein-1 (AP-1)/Jun, promoted expression of Siglec-F in mouse neutrophils and ALOX15 in mouse and human neutrophils. In patients with respiratory failure, ALOX15 + neutrophils were present in the bronchoalveolar lavage samples, and their frequency correlated with improved oxygenation. Thus, Siglec-F + ALOX15 + proresolving neutrophils contribute to tissue injury responses.
- 19 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (114) , eaeb2657
Siglec-F + neutrophils promote the resolution of acute lung injury through ALOX15 induction
Neutrophils have vital proinflammatory protective functions, but gene expression changes in neutrophils found in inflamed tissues suggest additional proresolving effects. We identified a neutrophil subset with a distinct phenotype and function that emerges in mouse lungs during resolution of injury. These resolution-phase neutrophils increased expression of Siglec-F (sialic acid–binding Ig-like lectin F), Alox15 (12/15-lipoxygenase), and Csf1 ( colony-stimulating factor 1 ). Siglec-F + neutrophils promoted macrophage differentiation and produced specialized proresolving mediators that accelerated injury resolution. Neutrophil depletion hindered lung epithelial catabatic responses, whereas adoptive transfer of Siglec-F + neutrophils accelerated restitution of lung epithelial cells. Transforming growth factor–β (TGF-β) and granulocyte-macrophage colony-stimulating factor (GM-CSF), acting via activator protein-1 (AP-1)/Jun, promoted expression of Siglec-F in mouse neutrophils and ALOX15 in mouse and human neutrophils. In patients with respiratory failure, ALOX15 + neutrophils were present in the bronchoalveolar lavage samples, and their frequency correlated with improved oxygenation. Thus, Siglec-F + ALOX15 + proresolving neutrophils contribute to tissue injury responses.
- 1 May 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (5) , 803-813
Select Airway Specialized Proresolving Mediators Are Associated with Recovery from Nonviral Chronic Obstructive Pulmonary Disease Exacerbations
Rationale: Recovery from chronic obstructive pulmonary disease (COPD) exacerbations is heterogeneous and has a profound impact on disease trajectories. Resolution of airway inflammation is an active process that may be driven by specialized proresolving mediators (SPMs). Objectives: We sought to characterize the temporal change in SPMs in the sputum of patients with COPD during exacerbations, their association with exacerbation triggers, and exacerbation recovery. Methods: Participants were recruited from the London COPD Exacerbation Cohort between January 11, 2016, and April 30, 2018. Participants were reviewed at baseline, exacerbation onset, 1 week, 2 weeks, and 6 weeks during their exacerbation recovery. Sputum collection, nasopharyngeal swabs, phlebotomy, quality-of-life questionnaires, and spirometry were performed at each visit. SPMs were measured in sputum by liquid chromatography–tandem mass spectrometry. Respiratory viruses were measured by quantitative PCR and bacteria by microbiological culture. Measurements and Main Results: There were 68 exacerbations during the study period. Median time to symptomatic recovery was 21 days for viral exacerbations, compared with 13 days in nonviral exacerbations (P < 0.001). There was a significant increase in resolvin D1 (RvD1) at exacerbation onset in bacterial exacerbations but not in viral exacerbations. Lower levels of RvD1 were associated with prolonged respiratory symptoms during the 1-week and 2-week recovery time points. Exogenous RvD1 significantly reduced IL-6 and CXCL8 response to rhinovirus infection in COPD bronchial epithelial cells. Conclusions: There is a dynamic temporal change in airway SPMs during COPD exacerbations. Reduced levels of RvD1 were associated with prolonged respiratory symptoms. SPMs may be a potential therapeutic approach to promote exacerbation recovery.
- 1 May 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (5) , 803-813
Select Airway Specialized Proresolving Mediators Are Associated with Recovery from Nonviral Chronic Obstructive Pulmonary Disease Exacerbations
Rationale: Recovery from chronic obstructive pulmonary disease (COPD) exacerbations is heterogeneous and has a profound impact on disease trajectories. Resolution of airway inflammation is an active process that may be driven by specialized proresolving mediators (SPMs). Objectives: We sought to characterize the temporal change in SPMs in the sputum of patients with COPD during exacerbations, their association with exacerbation triggers, and exacerbation recovery. Methods: Participants were recruited from the London COPD Exacerbation Cohort between January 11, 2016, and April 30, 2018. Participants were reviewed at baseline, exacerbation onset, 1 week, 2 weeks, and 6 weeks during their exacerbation recovery. Sputum collection, nasopharyngeal swabs, phlebotomy, quality-of-life questionnaires, and spirometry were performed at each visit. SPMs were measured in sputum by liquid chromatography–tandem mass spectrometry. Respiratory viruses were measured by quantitative PCR and bacteria by microbiological culture. Measurements and Main Results: There were 68 exacerbations during the study period. Median time to symptomatic recovery was 21 days for viral exacerbations, compared with 13 days in nonviral exacerbations (P < 0.001). There was a significant increase in resolvin D1 (RvD1) at exacerbation onset in bacterial exacerbations but not in viral exacerbations. Lower levels of RvD1 were associated with prolonged respiratory symptoms during the 1-week and 2-week recovery time points. Exogenous RvD1 significantly reduced IL-6 and CXCL8 response to rhinovirus infection in COPD bronchial epithelial cells. Conclusions: There is a dynamic temporal change in airway SPMs during COPD exacerbations. Reduced levels of RvD1 were associated with prolonged respiratory symptoms. SPMs may be a potential therapeutic approach to promote exacerbation recovery.
- 9 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (768) , eado6606
An altered natural killer cell immunophenotype characterizes clinically severe pediatric RSV infection
Respiratory syncytial virus (RSV) infects nearly all children by 2 years of age and is a leading cause of pediatric hospitalizations. A subset of children with RSV infection (RSV + children) develop respiratory failure requiring intensive care, but immune mechanisms distinguishing severe pediatric RSV infection are not fully elucidated. Natural killer (NK) cells are key innate immune effectors of viral host defense. In this study of 47 critically ill RSV + children, we coupled NK cell immunophenotype and cytotoxic function with clinical parameters to identify an NK cell immune signature of severe pediatric RSV disease. Airway NK cells were increased in intubated RSV + children with severe hypoxemia and prolonged duration of mechanical ventilation and were correlated with clinical severity scores. Peripheral blood NK cells were decreased in RSV + patients and had altered activating receptor expression, with increased expression of CD69 and decreased expression of NKG2D. Ex vivo, circulating NK cells from RSV + patients exhibited functional impairment characterized by decreased cytotoxicity as well as aberrant immune synapse assembly and lytic granule trafficking. NK cell frequency and phenotype correlated with clinical measures that defined disease severity. These findings implicate a role for NK cells in mediating RSV immunopathology and suggest that an altered NK cell immunophenotype is associated with severe RSV disease in young children.
- 9 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (768) , eado6606
An altered natural killer cell immunophenotype characterizes clinically severe pediatric RSV infection
Respiratory syncytial virus (RSV) infects nearly all children by 2 years of age and is a leading cause of pediatric hospitalizations. A subset of children with RSV infection (RSV + children) develop respiratory failure requiring intensive care, but immune mechanisms distinguishing severe pediatric RSV infection are not fully elucidated. Natural killer (NK) cells are key innate immune effectors of viral host defense. In this study of 47 critically ill RSV + children, we coupled NK cell immunophenotype and cytotoxic function with clinical parameters to identify an NK cell immune signature of severe pediatric RSV disease. Airway NK cells were increased in intubated RSV + children with severe hypoxemia and prolonged duration of mechanical ventilation and were correlated with clinical severity scores. Peripheral blood NK cells were decreased in RSV + patients and had altered activating receptor expression, with increased expression of CD69 and decreased expression of NKG2D. Ex vivo, circulating NK cells from RSV + patients exhibited functional impairment characterized by decreased cytotoxicity as well as aberrant immune synapse assembly and lytic granule trafficking. NK cell frequency and phenotype correlated with clinical measures that defined disease severity. These findings implicate a role for NK cells in mediating RSV immunopathology and suggest that an altered NK cell immunophenotype is associated with severe RSV disease in young children.
- 11 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (14) , e23807
15‐epi‐lipoxin A 5 promotes neutrophil exit from exudates for clearance by splenic macrophages
Specialized proresolving mediators (SPMs) promote local macrophage efferocytosis but excess leukocytes early in inflammation require additional leukocyte clearance mechanism for resolution. Here, neutrophil clearance mechanisms from localized acute inflammation were investigated in mouse dorsal air pouches. 15‐HEPE (15‐hydroxy‐5 Z ,8 Z ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid) levels were increased in the exudates. Activated human neutrophils converted 15‐HEPE to lipoxin A 5 (5 S ,6 R ,15 S ‐trihydroxy‐7 E ,9 E ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid), 15‐epi‐lipoxin A 5 (5 S ,6 R ,15 R ‐trihydroxy‐7 E ,9 E ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid), and resolvin E4 (RvE4; 5 S ,15 S ‐dihydroxy‐6 E ,8 Z ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid). Exogenous 15‐epi‐lipoxin A 5 , 15‐epi‐lipoxin A 4 and a structural lipoxin mimetic significantly decreased exudate neutrophils and increased local tissue macrophage efferocytosis, with comparison to naproxen. 15‐epi‐lipoxin A 5 also cleared exudate neutrophils faster than the apparent local capacity for stimulated macrophage efferocytosis, so the fate of exudate neutrophils was tracked with CD45.1 variant neutrophils. 15‐epi‐lipoxin A 5 augmented the exit of adoptively transferred neutrophils from the pouch exudate to the spleen, and significantly increased splenic SIRPa + and MARCO + macrophage efferocytosis. Together, these findings demonstrate new systemic resolution mechanisms for 15‐epi‐lipoxin A 5 and RvE4 in localized tissue inflammation, which distally engage the spleen to activate macrophage efferocytosis for the clearance of tissue exudate neutrophils.
- 11 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (14) , e23807
15‐epi‐lipoxin A 5 promotes neutrophil exit from exudates for clearance by splenic macrophages
Specialized proresolving mediators (SPMs) promote local macrophage efferocytosis but excess leukocytes early in inflammation require additional leukocyte clearance mechanism for resolution. Here, neutrophil clearance mechanisms from localized acute inflammation were investigated in mouse dorsal air pouches. 15‐HEPE (15‐hydroxy‐5 Z ,8 Z ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid) levels were increased in the exudates. Activated human neutrophils converted 15‐HEPE to lipoxin A 5 (5 S ,6 R ,15 S ‐trihydroxy‐7 E ,9 E ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid), 15‐epi‐lipoxin A 5 (5 S ,6 R ,15 R ‐trihydroxy‐7 E ,9 E ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid), and resolvin E4 (RvE4; 5 S ,15 S ‐dihydroxy‐6 E ,8 Z ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid). Exogenous 15‐epi‐lipoxin A 5 , 15‐epi‐lipoxin A 4 and a structural lipoxin mimetic significantly decreased exudate neutrophils and increased local tissue macrophage efferocytosis, with comparison to naproxen. 15‐epi‐lipoxin A 5 also cleared exudate neutrophils faster than the apparent local capacity for stimulated macrophage efferocytosis, so the fate of exudate neutrophils was tracked with CD45.1 variant neutrophils. 15‐epi‐lipoxin A 5 augmented the exit of adoptively transferred neutrophils from the pouch exudate to the spleen, and significantly increased splenic SIRPa + and MARCO + macrophage efferocytosis. Together, these findings demonstrate new systemic resolution mechanisms for 15‐epi‐lipoxin A 5 and RvE4 in localized tissue inflammation, which distally engage the spleen to activate macrophage efferocytosis for the clearance of tissue exudate neutrophils.
- Open Access
- 3 June 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (6) , e2416852
Pediatric Respiratory Syncytial Virus Hospitalizations and Respiratory Support After the COVID-19 Pandemic
Importance: After the COVID-19 pandemic, there was a surge of pediatric respiratory syncytial virus (RSV) infections, but national data on hospitalization and intensive care unit use and advanced respiratory support modalities have not been reported.Objective: To analyze demographics, respiratory support modes, and clinical outcomes of children with RSV infections at tertiary pediatric hospitals from 2017 to 2023.Design, Setting, and Participants: This cross-sectional study evaluated children from 48 freestanding US children’s hospitals registered in the Pediatric Health Information System (PHIS) database. Patients 5 years or younger with RSV from July 1, 2017, to June 30, 2023, were included. Each season was defined from July 1 to June 30. Prepandemic RSV seasons included 2017 to 2018, 2018 to 2019, and 2019 to 2020. The postpandemic season was delineated as 2022 to 2023.Exposure: Hospital presentation with RSV infection.Main Outcomes and Measures: Data on emergency department presentations, hospital or intensive care unit admission and length of stay, demographics, respiratory support use, mortality, and cardiopulmonary resuscitation were analyzed. Postpandemic season data were compared with prepandemic seasonal averages.Results: A total of 288 816 children aged 5 years or younger (median [IQR] age, 8.9 [3.3-21.5] months; 159 348 [55.2%] male) presented to 48 US children’s hospitals with RSV from July 1, 2017, to June 30, 2023. Respiratory syncytial virus hospital presentations increased from 39 698 before the COVID-19 pandemic to 94 347 after the pandemic (P < .001), with 86.7% more hospitalizations than before the pandemic (50 619 vs 27 114; P < .001). In 2022 to 2023, children were older (median [IQR] age, 11.3 [4.1-26.6] months vs 6.8 [2.6-16.8] months; P < .001) and had fewer comorbidities (17.6% vs 21.8% of hospitalized patients; P < .001) than during prepandemic seasons. Advanced respiratory support use increased 70.1% in 2022 to 2023 (9094 vs 5340; P < .001), and children requiring high-flow nasal cannula (HFNC) or noninvasive ventilation (NIV) were older than during prepandemic seasons (median [IQR] age for HFNC, 6.9 [2.7-16.0] months vs 4.6 [2.0-11.7] months; for NIV, 6.0 [2.1-16.5] months vs 4.3 [1.9-11.9] months). Comorbid conditions were less frequent after the pandemic across all respiratory support modalities (HFNC, 14.9% vs 19.1%, NIV, 22.0% vs 28.5%, invasive mechanical ventilation, 30.5% vs 38.0%; P < .001).Conclusions and Relevance: This cross-sectional study identified a postpandemic pediatric RSV surge that resulted in markedly increased hospital volumes and advanced respiratory support needs in older children with fewer comorbidities than prepandemic seasons. These clinical trends may inform novel vaccine allocation to reduce the overall burden during future RSV seasons.
- 3 June 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (6) , e2416852
Open AccessPediatric Respiratory Syncytial Virus Hospitalizations and Respiratory Support After the COVID-19 Pandemic
Importance: After the COVID-19 pandemic, there was a surge of pediatric respiratory syncytial virus (RSV) infections, but national data on hospitalization and intensive care unit use and advanced respiratory support modalities have not been reported.Objective: To analyze demographics, respiratory support modes, and clinical outcomes of children with RSV infections at tertiary pediatric hospitals from 2017 to 2023.Design, Setting, and Participants: This cross-sectional study evaluated children from 48 freestanding US children’s hospitals registered in the Pediatric Health Information System (PHIS) database. Patients 5 years or younger with RSV from July 1, 2017, to June 30, 2023, were included. Each season was defined from July 1 to June 30. Prepandemic RSV seasons included 2017 to 2018, 2018 to 2019, and 2019 to 2020. The postpandemic season was delineated as 2022 to 2023.Exposure: Hospital presentation with RSV infection.Main Outcomes and Measures: Data on emergency department presentations, hospital or intensive care unit admission and length of stay, demographics, respiratory support use, mortality, and cardiopulmonary resuscitation were analyzed. Postpandemic season data were compared with prepandemic seasonal averages.Results: A total of 288 816 children aged 5 years or younger (median [IQR] age, 8.9 [3.3-21.5] months; 159 348 [55.2%] male) presented to 48 US children’s hospitals with RSV from July 1, 2017, to June 30, 2023. Respiratory syncytial virus hospital presentations increased from 39 698 before the COVID-19 pandemic to 94 347 after the pandemic (P < .001), with 86.7% more hospitalizations than before the pandemic (50 619 vs 27 114; P < .001). In 2022 to 2023, children were older (median [IQR] age, 11.3 [4.1-26.6] months vs 6.8 [2.6-16.8] months; P < .001) and had fewer comorbidities (17.6% vs 21.8% of hospitalized patients; P < .001) than during prepandemic seasons. Advanced respiratory support use increased 70.1% in 2022 to 2023 (9094 vs 5340; P < .001), and children requiring high-flow nasal cannula (HFNC) or noninvasive ventilation (NIV) were older than during prepandemic seasons (median [IQR] age for HFNC, 6.9 [2.7-16.0] months vs 4.6 [2.0-11.7] months; for NIV, 6.0 [2.1-16.5] months vs 4.3 [1.9-11.9] months). Comorbid conditions were less frequent after the pandemic across all respiratory support modalities (HFNC, 14.9% vs 19.1%, NIV, 22.0% vs 28.5%, invasive mechanical ventilation, 30.5% vs 38.0%; P < .001).Conclusions and Relevance: This cross-sectional study identified a postpandemic pediatric RSV surge that resulted in markedly increased hospital volumes and advanced respiratory support needs in older children with fewer comorbidities than prepandemic seasons. These clinical trends may inform novel vaccine allocation to reduce the overall burden during future RSV seasons.
- Open Access
- 3 April 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Vitamin D constrains inflammation by modulating the expression of key genes on Chr17q12-21.1
Vitamin D possesses immunomodulatory functions and vitamin D deficiency has been associated with the rise in chronic inflammatory diseases, including asthma (Litonjua and Weiss, 2007). Vitamin D supplementation studies do not provide insight into the molecular genetic mechanisms of vitamin D-mediated immunoregulation. Here, we provide evidence for vitamin D regulation of two human chromosomal loci, Chr17q12-21.1 and Chr17q21.2, reliably associated with autoimmune and chronic inflammatory diseases. We demonstrate increased vitamin D receptor (Vdr) expression in mouse lung CD4+ Th2 cells, differential expression of Chr17q12-21.1 and Chr17q21.2 genes in Th2 cells based on vitamin D status and identify the IL-2/Stat5 pathway as a target of vitamin D signaling. Vitamin D deficiency caused severe lung inflammation after allergen challenge in mice that was prevented by long-term prenatal vitamin D supplementation. Mechanistically, vitamin D induced the expression of the Ikzf3-encoded protein Aiolos to suppress IL-2 signaling and ameliorate cytokine production in Th2 cells. These translational findings demonstrate mechanisms for the immune protective effect of vitamin D in allergic lung inflammation with a strong molecular genetic link to the regulation of both Chr17q12-21.1 and Chr17q21.2 genes and suggest further functional studies and interventional strategies for long-term prevention of asthma and other autoimmune disorders.
- 3 April 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessVitamin D constrains inflammation by modulating the expression of key genes on Chr17q12-21.1
Vitamin D possesses immunomodulatory functions and vitamin D deficiency has been associated with the rise in chronic inflammatory diseases, including asthma (Litonjua and Weiss, 2007). Vitamin D supplementation studies do not provide insight into the molecular genetic mechanisms of vitamin D-mediated immunoregulation. Here, we provide evidence for vitamin D regulation of two human chromosomal loci, Chr17q12-21.1 and Chr17q21.2, reliably associated with autoimmune and chronic inflammatory diseases. We demonstrate increased vitamin D receptor (Vdr) expression in mouse lung CD4+ Th2 cells, differential expression of Chr17q12-21.1 and Chr17q21.2 genes in Th2 cells based on vitamin D status and identify the IL-2/Stat5 pathway as a target of vitamin D signaling. Vitamin D deficiency caused severe lung inflammation after allergen challenge in mice that was prevented by long-term prenatal vitamin D supplementation. Mechanistically, vitamin D induced the expression of the Ikzf3-encoded protein Aiolos to suppress IL-2 signaling and ameliorate cytokine production in Th2 cells. These translational findings demonstrate mechanisms for the immune protective effect of vitamin D in allergic lung inflammation with a strong molecular genetic link to the regulation of both Chr17q12-21.1 and Chr17q21.2 genes and suggest further functional studies and interventional strategies for long-term prevention of asthma and other autoimmune disorders.
- Open Access
- 3 January 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (2)
The Maresin 1–LGR6 axis decreases respiratory syncytial virus-induced lung inflammation
The resolution of infection is an active process with specific molecular and cellular mechanisms that temper inflammation and enhance pathogen clearance. Here, the specialized pro-resolving mediator (SPM) Maresin 1 (MaR1) inhibited respiratory syncytial virus (RSV)-induced inflammation. inlerleukin-13 production from type 2 innate lymphoid cells (ILC) and CD4 T helper type 2 cells was decreased by exogenous MaR1. In addition, MaR1 increased amphiregulin production and decreased RSV viral transcripts to promote resolution. MaR1 also promoted interferon-β production in mouse lung tissues and also in pediatric lung slices. MaR1 significantly inhibited the RSV-triggered aberrant inflammatory phenotype in FoxP3-expressing Tregs. The receptor for MaR1, leucine-rich repeat-containing G protein-coupled receptor 6 (LGR6), was constitutively expressed on Tregs. Following RSV infection, mice lacking Lgr6 had exacerbated type 2 immune responses with an increased viral burden and blunted responses to MaR1. Together, these findings have uncovered a multi-pronged protective signaling axis for MaR1–Lgr6, improving Tregs’s suppressive function and upregulating host antiviral genes resulting in decreased viral burden and pathogen-mediated inflammation, ultimately promoting restoration of airway mucosal homeostasis.
- 3 January 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (2)
Open AccessThe Maresin 1–LGR6 axis decreases respiratory syncytial virus-induced lung inflammation
The resolution of infection is an active process with specific molecular and cellular mechanisms that temper inflammation and enhance pathogen clearance. Here, the specialized pro-resolving mediator (SPM) Maresin 1 (MaR1) inhibited respiratory syncytial virus (RSV)-induced inflammation. inlerleukin-13 production from type 2 innate lymphoid cells (ILC) and CD4 T helper type 2 cells was decreased by exogenous MaR1. In addition, MaR1 increased amphiregulin production and decreased RSV viral transcripts to promote resolution. MaR1 also promoted interferon-β production in mouse lung tissues and also in pediatric lung slices. MaR1 significantly inhibited the RSV-triggered aberrant inflammatory phenotype in FoxP3-expressing Tregs. The receptor for MaR1, leucine-rich repeat-containing G protein-coupled receptor 6 (LGR6), was constitutively expressed on Tregs. Following RSV infection, mice lacking Lgr6 had exacerbated type 2 immune responses with an increased viral burden and blunted responses to MaR1. Together, these findings have uncovered a multi-pronged protective signaling axis for MaR1–Lgr6, improving Tregs’s suppressive function and upregulating host antiviral genes resulting in decreased viral burden and pathogen-mediated inflammation, ultimately promoting restoration of airway mucosal homeostasis.